For example, PTEN-deficient breast cancer cells are resistant to the pan-PI3K inhibitor GDC-0941 and PI3K/mTOR dual inhibitor BEZ-235, unlike those harboring mutations in PIK3CA and HER219–21. This evidence concerns the gene PIK3CA and breast cancer.